Professor
Michael Roden
Author

Michael Roden graduated from University of Vienna, Austria in 1986, was trained at General Hospital Vienna and performed research as Max-Kade fellow at Yale University, CT, USA. He is certified in internal medicine, endocrinology, diabetology and metabolic disease (Austria, Germany) and clinical pharmacology (Austria). From 2003 to 2008, he was the head of the 1st medical department with diabetology, gastroenterology and nephrology at Hanusch Hospital Vienna and professor at its university teaching hospital. Since 2008, he is the chair and full professor of endocrinology and metabolic diseases at Heinrich-Heine University Düsseldorf and the director of the department of endocrinology and diabetology at University Hospital Düsseldorf. In parallel, he is the chief scientific officer of the German Diabetes Center (DDZ) and a speaker of the German Center for Diabetes Research (DZD).

His translational research addresses insulin resistance and energy metabolism, specifically using non-invasive technologies, as well as diabetes and its comorbidities, particularly steatotic liver diseases. More recently, he is also focusing on diabetes sub-/endotyping and driving precision medicine in diabetology. He has published more than 800 peer-reviewed papers (e.g. in Nature, Lancet, Cell Metab …) and is a Highly Cited Researcher (Clarivate) since 2022. He received several awards (e.g. Oskar-Minkowski Prize by EASD, G. B. Morgagni Gold Medal by Univ. Pisa, Paul-Langerhans Medal by the German Diabetes Association, DDG) and holds honorary doctorates of the Universities of Athens and Belgrade, honorary membership of the Hungarian Diabetes Association and a collaborative professorship of Kanazawa University in Japan.

Professor Roden was chairman of EFSD, honorary treasurer of EASD and EFSD, president of the Central European Diabetes Association, the Austrian Diabetes Association and Congress President of DDG. From 2016 to 2021, he served as head of the Committee Medicine of the German Council of Science and Humanities, appointed by the President of Germany. Recently, he has been also selected as a member of the Academia Europea and the German National Academy of Sciences Leopoldina.

Duality of Interest: Professor Roden has received honoraria for advisory boards, lectures or other educational activities from AstraZeneca, Boehringer-Ingelheim, Echosens, Madrigal, MSD, Novo Nordisk and Synlab.

Date: February 2025



Contribution to the EASD e-Learning programme
Course: Management of metabolic dysfunction-associated steatotic liver disease (MASLD) Course: Non-alcoholic fatty liver disease